Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Non-Myeloablative HSCT for Severe Sickle Cell Disease
NCT03421756Phase 1Terminated
- Start
- Mar 2018
- Primary completion
- Sep 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of alemtuzumab in sickle cell disease (SCD). Primary endpoint: Treatment Success at 1 year. Started Mar 2018; status: terminated.
02
Drugs
alemtuzumab
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT03421756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03421756.